Phase I bioequivalence trial of aspirin/omeprazole to enteric-coated aspirin 325mg using acetylsalicylic acid as the analyte.

Trial Profile

Phase I bioequivalence trial of aspirin/omeprazole to enteric-coated aspirin 325mg using acetylsalicylic acid as the analyte.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2014

At a glance

  • Drugs Aspirin/omeprazole (Primary) ; Aspirin
  • Indications Cardiovascular disorders; NSAID-induced ulcer; Thrombosis
  • Focus Pharmacokinetics; Registrational
  • Most Recent Events

    • 25 Jun 2012 New trial record
    • 01 May 2012 POZEN has completed a phase I bioequivalence trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top